Fairfield Bush & CO. reduced its stake in shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 4.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 34,537 shares of the company’s stock after selling 1,599 shares during the period. Fairfield Bush & CO.’s holdings in Roche Holdings AG Basel were worth $1,401,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Headinvest LLC raised its position in Roche Holdings AG Basel by 9.7% in the 1st quarter. Headinvest LLC now owns 75,540 shares of the company’s stock worth $2,598,000 after purchasing an additional 6,680 shares during the period. Dearborn Partners LLC increased its position in shares of Roche Holdings AG Basel by 9.5% in the first quarter. Dearborn Partners LLC now owns 11,485 shares of the company’s stock valued at $466,000 after acquiring an additional 1,000 shares during the period. Boston Private Wealth LLC increased its position in shares of Roche Holdings AG Basel by 64.8% in the first quarter. Boston Private Wealth LLC now owns 16,534 shares of the company’s stock valued at $670,000 after acquiring an additional 6,504 shares during the period. Hancock Whitney Corp purchased a new position in shares of Roche Holdings AG Basel in the first quarter valued at about $818,000. Finally, Moloney Securities Asset Management LLC increased its position in shares of Roche Holdings AG Basel by 4.3% in the first quarter. Moloney Securities Asset Management LLC now owns 66,932 shares of the company’s stock valued at $2,716,000 after acquiring an additional 2,769 shares during the period. 0.30% of the stock is owned by institutional investors.

Several research firms recently commented on RHHBY. Goldman Sachs Group raised shares of Roche Holdings AG Basel from a “buy” rating to a “conviction-buy” rating in a research note on Tuesday, March 10th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Roche Holdings AG Basel in a research note on Thursday, April 23rd. ValuEngine downgraded shares of Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a research note on Friday, May 1st. Citigroup upgraded shares of Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 18th. Finally, Wolfe Research upgraded shares of Roche Holdings AG Basel from a “market perform” rating to an “outperform” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Roche Holdings AG Basel currently has an average rating of “Buy” and an average target price of $48.00.

RHHBY stock traded up $0.37 during midday trading on Wednesday, reaching $43.80. 1,341,417 shares of the company’s stock traded hands, compared to its average volume of 2,495,607. Roche Holdings AG Basel ADR has a 52-week low of $32.95 and a 52-week high of $46.00. The stock has a market cap of $299.96 billion, a P/E ratio of 17.24, a PEG ratio of 3.05 and a beta of 0.40. The company has a current ratio of 1.30, a quick ratio of 1.04 and a debt-to-equity ratio of 0.35. The stock’s 50-day moving average is $43.73 and its 200 day moving average is $41.16.

Roche Holdings AG Basel Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

See Also: Trading Strategy Methods for Individual Investors

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.